Abstract
[1] Shlipak M., Diabetic nephropathy, Clin Evid (Online), 2009, 0606 Search in Google Scholar
[2] Conway B.R., Maxwell A.P., Genetics of diabetic nephropathy: are there clues to the understanding of common kidney diseases? Nephron. Clin. Pract., 2009, 112, 213–221 http://dx.doi.org/10.1159/00022478710.1159/000224787Search in Google Scholar PubMed
[3] Carpena M.P., Rados D.V., Sortica D.A., deSouza B.M., Reis A.F., Canani L.H., et al., Genetics of diabetic nephropathy, Arq. Bras. Endocrinol. Metab., 2010, 54, 254–261 http://dx.doi.org/10.1590/S0004-2730201000030000210.1590/S0004-27302010000300002Search in Google Scholar PubMed
[4] Gnudi L., Goldsmith D., Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes, F1000 Med Rep, 2010, 2, 18 10.3410/M2-18Search in Google Scholar PubMed PubMed Central
[5] Baynes J W., Role of oxidative stress in development of complications in diabetes, Diabetes, 1991, 40, 405–412 http://dx.doi.org/10.2337/diabetes.40.4.40510.2337/diabetes.40.4.405Search in Google Scholar
[6] Ceriello A., dello Russo P., Amstad P., Cerutti P., High glucose induces antioxidant enzymes in human endothelial cells in culture, Evidence linking hyperglycemia and oxidative stress, Diabetes, 1996, 45, 471–477 10.2337/diabetes.45.4.471Search in Google Scholar
[7] Nishikawa T., Edelstein D., Brownlee M., The missing link: a single unifying mechanism for diabetic complications, Kidney Int. Suppl., 2000, 77, 26–30 http://dx.doi.org/10.1046/j.1523-1755.2000.07705.x10.1046/j.1523-1755.2000.07705.xSearch in Google Scholar PubMed
[8] Brownlee M., The Pathobiology of Diabetic Complications, A unifying Mechanism, Diabetes, 2005, 54, 1615–1625 10.2337/diabetes.54.6.1615Search in Google Scholar PubMed
[9] Forbes J., Coughlan M.T., Cooper M.E., Oxidative stress as a major culprit in kidney disease in diabetes, Diabetes, 2008, 57, 1446–1454 http://dx.doi.org/10.2337/db08-005710.2337/db08-0057Search in Google Scholar PubMed
[10] Kim J., We, Y., Sowers J.R., Role of mitochondrial dysfunction in insulin resistance, Circ. Res., 2008, 102, 401–414 http://dx.doi.org/10.1161/CIRCRESAHA.107.16547210.1161/CIRCRESAHA.107.165472Search in Google Scholar PubMed PubMed Central
[11] Gao L., Mann G.E., Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signaling, Cardiovasc. Res., 2009, 82, 19–20 http://dx.doi.org/10.1093/cvr/cvp03110.1093/cvr/cvp031Search in Google Scholar PubMed
[12] Yamagishi S., Matsui T, Advanced glycation end products, oxidative stress and diabetic nephropathy, Oxid. Med. Cell. Longev., 2010, 32, 101–108 http://dx.doi.org/10.4161/oxim.3.2.1114810.4161/oxim.3.2.11148Search in Google Scholar
[13] Takayanagi R., Inoguchi T., Ohnaka K., Clinical and experimental evidence for oxidative stress as an exacerbating factor of diabetes mellitus, J. Clin. Biochem. Nutr., 2011, 48, 72–77 http://dx.doi.org/10.3164/jcbn.11-014FR10.3164/jcbn.11-014FRSearch in Google Scholar
[14] Wink D.A., Miranda K.M., Espey M.G., Cytotoxicity related to oxidative and nitrosative stress by nitric oxide, Exp. Biol. Med., 2001, 226, 621–623 10.1177/153537020222600704Search in Google Scholar
[15] Valavanidis A., Vlachogianni T., Fiotakis C., 8-hydroxy-2′-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis, J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev., 2009, 27, 120–139 http://dx.doi.org/10.1080/1059050090288568410.1080/10590500902885684Search in Google Scholar
[16] Halliwell B., Why and how should we measure oxidative DNA damage in nutritional studies? How far have we come? Am. J. Clin. Nutr., 2000, 72, 1082–1087 10.1093/ajcn/72.5.1082Search in Google Scholar
[17] Al-Aubaidy H.A., Jelinek H.F., 8-Hydroxy-2-deoxyguanosine identifies oxidative DNA damage in a rural prediabetes cohort, Redox Rep., 2010, 15, 155–160 http://dx.doi.org/10.1179/174329210X1265050662368110.1179/174329210X12650506623681Search in Google Scholar
[18] Dincer Y., Sekercioglu N., Pekpak M., Gunes K.N., Akcay T., Assessment of DNA oxidation and antioxidant activity in hypertensive patients with chronic kidney disease, Ren. Fail., 2008, 30, 1006–1011 http://dx.doi.org/10.1080/0886022080242204410.1080/08860220802422044Search in Google Scholar
[19] Pan H.Z., Zhang L., Guo M.Y., Sui H., Li H., Wu W.H., et al., The oxidative stress status in diabetes mellitus and diabetic nephropathy, Acta Diabetol., 2010, 47, 71–76 http://dx.doi.org/10.1007/s00592-009-0128-110.1007/s00592-009-0128-1Search in Google Scholar
[20] Zelko I.N., Mariani T.J., Folz R.J., Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and ECSOD (SOD3) gene structures, evolution, and expression, Free Radic. Biol. Med., 2002, 33, 337–349 http://dx.doi.org/10.1016/S0891-5849(02)00905-X10.1016/S0891-5849(02)00905-XSearch in Google Scholar
[21] Goyal M.M., Basak A., Human catalase: looking for complete identity, Protein Cell, 2010, 1, 888–897 http://dx.doi.org/10.1007/s13238-010-0113-z10.1007/s13238-010-0113-zSearch in Google Scholar PubMed PubMed Central
[22] Josephy, P.D., Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology, Hum. Genomics Proteomics, 2010, 876940 10.4061/2010/876940Search in Google Scholar PubMed PubMed Central
[23] Loria V., Dato I., Graziani F., Biasucci L.M., Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes, Mediators Inflamm., 2008, 135625 10.1155/2008/135625Search in Google Scholar PubMed PubMed Central
[24] Schindhelm R.K., van der Zwan L.P., Teerlink T., Scheffer P.G. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin. Chem., 2009, 55, 1462–1470 http://dx.doi.org/10.1373/clinchem.2009.12602910.1373/clinchem.2009.126029Search in Google Scholar PubMed
[25] Paravicini T.M., Touyz R.M., NADPH oxidases, reactive oxygen species and hypertension, Diab. Care, 2008, 31, 170–180 http://dx.doi.org/10.2337/dc08-s24710.2337/dc08-s247Search in Google Scholar PubMed
[26] Makuc J., Petrovič D., A Review Of Oxidative Stress Related Genes And New Antioxidant Therapy In Diabetic Nephropathy, Cardiovasc. Hematol. Agents Med. Chem., 2012, 9, 253–261 http://dx.doi.org/10.2174/18715251179812094910.2174/187152511798120949Search in Google Scholar PubMed
[27] World Health Organization, Part 1: Diagnosis and Classification of Diabetes Mellitus: Report of a WHO consultation, In: Alwan A., King H., (Eds.), Definition, diagnosis and classification of diabetes mellitus and its complications, World Health Department of Noncommunicable Disease Surveillance, Geneva, 1999 Search in Google Scholar
[28] Makuc J., Petrovic D., No association between NOS2 and NOS3 polymorphisms and diabetic nephropathy in type 2 diabetics, Centr. Eur. J. Biol., 2012, 7, 404–410 http://dx.doi.org/10.2478/s11535-012-0033-410.2478/s11535-012-0033-4Search in Google Scholar
[29] Sutton A., Khoury H., Prip-Buus C., Cepanec C., Pessayre D., Degoul F., The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria, Pharmacogenetics, 2003, 13, 145–157 http://dx.doi.org/10.1097/00008571-200303000-0000410.1097/00008571-200303000-00004Search in Google Scholar
[30] Flekac M., Skrha J., Hilgertova J., Lacinova Z., Jarolimkova M., Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus, BMC Med. Genet., 2008, 9, 30 http://dx.doi.org/10.1186/1471-2350-9-3010.1186/1471-2350-9-30Search in Google Scholar PubMed PubMed Central
[31] Chistyakov D.A., Savostánov K.V., Zotova E.V., Nosikov V.V., Polymorphisms in the Mn-SOD and EC-SOD genes and their relationship to diabetic neuropathy in type 1 diabetes mellitus, BMC Med. Genet., 2001, 2, 4 http://dx.doi.org/10.1186/1471-2350-2-410.1186/1471-2350-2-4Search in Google Scholar PubMed PubMed Central
[32] Nomiyama T., Tanaka Y., Piap L., Nagasaka K., Sakai K., Ogihara T., et al., The polymorphism of manganese superoxide dismutase is associated with diabetic nephropathy in Japanese type 2 diabetic patients, J. Hum. Gen., 2003, 48, 138–141 10.1007/s100380300021Search in Google Scholar PubMed
[33] Lee S.J., Choi M.G., Kim D.S., Kim T. W., Manganese superoxide dismutase gene polymorphism (V16A) is associated with stages of albuminuria in Korean type 2 diabetic patients, Metabol., 2006, 55, 1–7 http://dx.doi.org/10.1016/j.metabol.2005.04.03010.1016/j.metabol.2005.04.030Search in Google Scholar
[34] Globocnik Petrovic M., Cilensek I., Petrovic D. Manganese superoxide dismutase gene polymorphism (V16A) is associated with diabetic retinopathy in Slovene (Caucasians) type 2 diabetes patients, Dis. Markers, 2008, 24, 59–64 10.1155/2008/940703Search in Google Scholar
[35] Hovnik T., Dolžan V., Ursic Bratina N., Trebusak Podkrajsek K., Battelino T., Genetic polymorphisms in genes encoding antioxidant enzymes are associated with diabetic retinopathy in type 1 diabetes, Diab. Care, 2009, 32, 2258–2262 http://dx.doi.org/10.2337/dc09-085210.2337/dc09-0852Search in Google Scholar
[36] Möllstein A., Jorsal A., Lajer M., Vionnet N., The V16A polymorphism in SOD2 is associated with increased risk of diabetic nephropathy and cardiovascular disease in typle 1 diabetes, Diabetologia, 2009, 52, 2590–2593 http://dx.doi.org/10.1007/s00125-009-1550-110.1007/s00125-009-1550-1Search in Google Scholar
[37] Tian C., Fang S., Du X., Jia C., Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta analysis, Diabetologia, 2011, 54, 803–811 http://dx.doi.org/10.1007/s00125-010-2004-510.1007/s00125-010-2004-5Search in Google Scholar
[38] Kedziora-Kornatowska K.Z., Luciak M., Blaszczyk J., Pawlak W., Lipid peroxidation and activities of antioxidant enzymes in erythrocytes of patients with non-insulin dependent diabetes with or without diabetic nephropathy, Nephrol. Dial. Transplant., 1998, 13, 2829–2832 http://dx.doi.org/10.1093/ndt/13.11.282910.1093/ndt/13.11.2829Search in Google Scholar
[39] Hodgkinson A.D., Bartlett T., Oates P.J., Millward B.A., The response of antioxidant genes to hyperglycaemia is abnormal in patients with type 1 diabetes and diabetic nephropathy, Diabetes, 2003, 52, 846–851 http://dx.doi.org/10.2337/diabetes.52.3.84610.2337/diabetes.52.3.846Search in Google Scholar
[40] Chistiakov D.A., Zotova E.V., Savostánov K.V., Bursa T.R., Galeev I.V., Strokov I.A., et al., The 262T>C promoter polymorphism of the catalase gene is associated with diabetic neuropathy in type 1 diabetic Russian patients, Diab. Metabol., 2006, 32, 63–68 http://dx.doi.org/10.1016/S1262-3636(07)70248-310.1016/S1262-3636(07)70248-3Search in Google Scholar
[41] Gorin Y., Block K., Hernandez J., Bhandari B., Wagner B., Brnes J.L., et al., Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney, J. Biol. Chem., 2005, 280, 39616–39626 http://dx.doi.org/10.1074/jbc.M50241220010.1074/jbc.M502412200Search in Google Scholar PubMed
[42] Hodgkinson A.D., Millward B.A., Demaine A.G., Association of the p22phox component of NAD(P)H oxidase with susceptibility to diabetic nephropathy in patients with type 1 diabetes, Diab. Care, 2003, 26, 3111–3115 http://dx.doi.org/10.2337/diacare.26.11.311110.2337/diacare.26.11.3111Search in Google Scholar PubMed
[43] Matsunaga-Irie S., Maruyama T., Yamamoto Y., Motohashi Y., Hirose H., Shimada A., et al., Relation between development of nephropathy and the p22phox C242T and receptor for advanced glycation end product G1704T gene polymorphisms in type 2 diabetic patients, Diab. Care, 2004, 27, 303–307 http://dx.doi.org/10.2337/diacare.27.2.30310.2337/diacare.27.2.303Search in Google Scholar PubMed
[44] Ewens K.G., George R.A., Sharma K., Zidayeh F.N., Speilman R.S., Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test, Diabetes, 2005, 54, 3305–3318 http://dx.doi.org/10.2337/diabetes.54.11.330510.2337/diabetes.54.11.3305Search in Google Scholar PubMed
[45] Inoue N., Kawashima S., Kanazawa K., Yamada S., Akita H., Yokoyama M., Polymorphism of the NADH/NADPH Oxidase p22 phox Gene in Patients With Coronary Artery Disease, Circulation, 1998, 97, 135–137 http://dx.doi.org/10.1161/01.CIR.97.2.13510.1161/01.CIR.97.2.135Search in Google Scholar
[46] Piedrafita F.J., Molander R.B., Vansant G., Orlova E.A., Pfahl M., Reynolds W.F., An Alu Element in the Myeloperoxidase Promoter Contains a Composite SP1-Thyroid Hormone-Retinoic Acid Response Element, J. Biol. Chem., 1996, 271, 14412–14420 http://dx.doi.org/10.1074/jbc.271.24.1441210.1074/jbc.271.24.14412Search in Google Scholar PubMed
[47] Ambrosone C.B., Ahn J., Singh K.K., Rezaishiraz H., Furberg H., Sweeney C., et al., Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer, Cancer Res., 2005, 65, 1105–1111 10.1158/0008-5472.1105.65.3Search in Google Scholar
[48] Gu F., Qureshi A.A., Kraft P., Guo Q., Hunter D.J., Han J., Polymorphisms in genes involved in DNA repair, cell growth, oxidative stress and inflammatory response, and melanoma risk, Br. J. Dermatol., 2009, 161, 209–212 http://dx.doi.org/10.1111/j.1365-2133.2009.09219.x10.1111/j.1365-2133.2009.09219.xSearch in Google Scholar PubMed PubMed Central
[49] He C., Tamimi R.M., Hankinson S.E., Hunter D.J., Han J., A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk, Breast Cancer Res. Treat., 2009, 113, 585–594 http://dx.doi.org/10.1007/s10549-008-9962-z10.1007/s10549-008-9962-zSearch in Google Scholar PubMed PubMed Central
[50] Yang Y., Kao M.T., Chang C.C., Chung S.Y., Chen C.M., Tsa, J.J., et al., Glutathione S-transferase T1 deletion is a risk factor for developing end-stage renal disease in diabetic patients, Int. J. Mol. Med., 2004, 14, 855–859 10.3892/ijmm.14.5.855Search in Google Scholar
[51] Doney A.S.F., Lee S., Leese G.P., Morris A.D., Palmer C.A.N., Increased cardiovascular morbidity and mortality in type 2 diabetes is associated with the gluthatione S-transferase theta-Null genotype: a Go-DARTS Study, Circulation, 2005, 111, 2927–2934 http://dx.doi.org/10.1161/CIRCULATIONAHA.104.50922410.1161/CIRCULATIONAHA.104.509224Search in Google Scholar PubMed
[52] Datta S.K., Kumar V., Ahmed R.S., Tripathi A.K., Kalra O.P., Banerjee B.D. Effect of GSTM1 and GSTT1 double deletions in the development of oxidative stress in diabetic nephropathy patients, Indian J. Biochem. Biophys., 2010, 47, 100–103 Search in Google Scholar
[53] Fujita H., Narita T., Meguro H., Shimotomai T., Kitazato H., Kagaya E., et al., No association of gluthatione S-transferase M1 gene polymorphism with diabetic nephropathy in Japanese type 2 diabetic patients, Ren. Fail., 2000, 22, 479–486 http://dx.doi.org/10.1081/JDI-10010088910.1081/JDI-100100889Search in Google Scholar PubMed
[54] Tiwari A.K., Prasad P., Thelma B.K., Prasanna Kumar K.M., Ammini A.C., Gupta A., et al., Oxidative stress pathway genes and chronic renal insufficiency in Asian Indians with type 2 diabetes, J. Diab. Comp., 2009, 23, 102–111 http://dx.doi.org/10.1016/j.jdiacomp.2007.10.00310.1016/j.jdiacomp.2007.10.003Search in Google Scholar PubMed
[55] Bid H.K., Konwar R., Saxena M., Chaudhari P., Agrawal C.G., Banerjee M. Association of gluthationeS-transferase (GSTM1, T1 and P1) gene polymorphisms with type 2 diabetes mellitus in north Indian population, JPGM, 2010, 56, 176–181 10.4103/0022-3859.68633Search in Google Scholar PubMed
© 2012 Versita Warsaw
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.